HIF1A and alcoholic fatty liver disease: In alcoholic fatty liver disease MitoQ has been observed to successfully prevent ethanol-induced oxidant-damage and liver steatosis through a mechanism involving ROS/reactive nitrogen species (RNS) scavenging and the suppression of Hypoxia-inducible factor 1-alpha (HIF1α) activation [79].